Company Overview of Broad Institute of MIT and Harvard
7 Cambridge Center
Cambridge, MA 02142
Key Executives for Broad Institute of MIT and Harvard
President and Founding Director
Associate Member and Director of Stanley Center for Psychiatric Research
Compensation as of Fiscal Year 2014.
Broad Institute of MIT and Harvard Key Developments
SAGE Labs Licenses CRISPR/Cas9 Technology from the Broad Institute
Jul 29 14
SAGE Labs Inc. announced that they have licensed CRISPR/Cas9 technology from the Broad Institute. The license enables SAGE Labs to use the CRISPR/Cas9 system to engineer cell and animal models for their clients as well as distribute validated CRISPR reagents. This is the second license obtained by SAGE Labs around CRISPR/Cas9 technology. The Broad Institute was recently issued the first patent for CRISPR/Cas9 technology based on the research of Feng Zhang, PhD, published in Science in January of 2013. CRISPR/Cas9 technology represents the latest advancement in nuclease-based gene editing tools, which have revolutionized genetic engineering by markedly reducing development times and enabling genetic engineering in potentially any species.
Horizon Discovery Enters into Non-Exclusive License Agreement with Broad Institute
Jun 12 14
Horizon Discovery™ Group plc announced it has entered into a non-exclusive license agreement with the Broad Institute to access intellectual property related to the CRISPR/Cas9 gene editing system. Under the terms of the agreement, Horizon has rights to use the technology commercially for applications including development of research tools and reagents, and provision of services that utilize CRISPR, for example as part of Horizon's GENASSIST™ offering.
Broad Institute of MIT and Harvard Announces Opening of Building at Cambridge's Kendall Square
May 21 14
The Broad Institute of MIT and Harvard announced the opening of a 375,000-square-foot research building at 75 Ames Street in Cambridge's Kendall Square. Mayor of Cambridge David Maher, as well as city and state representatives, will attend the ribbon-cutting ceremony with Broad Institute officials and board members. The new building, which seamlessly connects to the institute's 7 Cambridge Center location, consolidates the Broad's campus and reflects the Broad's core mission to bring together researchers from a variety of scientific disciplines to harness the power of genomics to transform the understanding and treatment of diseases. Research groups in the new building will be focused on many critical disease areas, including cancer, diabetes, cardiovascular disease, metabolic diseases, autoimmune diseases, psychiatric diseases, and more. The building's location also reflects the institute's enduring commitment to Kendall Square and its partner institutions in the surrounding community.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries